Cargando…
Editorial: Debates in cardiovascular pharmacology and drug discovery: 2022
Autores principales: | Xu, Keman, Saaoud, Fatma, Shao, Ying, Lu, Yifan, Jiang, Xiaohua, Wu, Sheng, Sun, Jianxin, Fernades Conti, Filipe, Martinez, Laisel, Vazquez-Padron, Roberto, Wang, Hong, Yang, Xiaofeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619719/ https://www.ncbi.nlm.nih.gov/pubmed/37920177 http://dx.doi.org/10.3389/fcvm.2023.1304680 |
Ejemplares similares
-
Editorial: Insights in cardiovascular therapeutics 2022—cardiovascular innate immunity
por: Xu, Keman, et al.
Publicado: (2023) -
Chronic Kidney Disease Transdifferentiates Veins into a Specialized Immune–Endocrine Organ with Increased MYCN-AP1 Signaling
por: Saaoud, Fatma, et al.
Publicado: (2023) -
Editorial: Debates in coronary artery disease: 2022
por: Cook, Stéphane
Publicado: (2023) -
Novel Knowledge-Based Transcriptomic Profiling of Lipid Lysophosphatidylinositol-Induced Endothelial Cell Activation
por: Xu, Keman, et al.
Publicado: (2021) -
Early hyperlipidemia triggers metabolomic reprogramming with increased SAH, increased acetyl-CoA-cholesterol synthesis, and decreased glycolysis
por: Xu, Keman, et al.
Publicado: (2023)